Last reviewed · How we verify
Honghuaruyi Wan
Honghuaruyi Wan is a Small molecule drug developed by Beijing University of Chinese Medicine. It is currently FDA-approved.
At a glance
| Generic name | Honghuaruyi Wan |
|---|---|
| Sponsor | Beijing University of Chinese Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Honghuaruyi Wan CI brief — competitive landscape report
- Honghuaruyi Wan updates RSS · CI watch RSS
- Beijing University of Chinese Medicine portfolio CI
Frequently asked questions about Honghuaruyi Wan
What is Honghuaruyi Wan?
Honghuaruyi Wan is a Small molecule drug developed by Beijing University of Chinese Medicine.
Who makes Honghuaruyi Wan?
Honghuaruyi Wan is developed and marketed by Beijing University of Chinese Medicine (see full Beijing University of Chinese Medicine pipeline at /company/beijing-university-of-chinese-medicine).
What development phase is Honghuaruyi Wan in?
Honghuaruyi Wan is FDA-approved (marketed).
Related
- Manufacturer: Beijing University of Chinese Medicine — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing